Gene therapy for articular cartilage repair by Trippel, Stephen et al.
SPECIAL ISSUE PAPER 451
Gene therapy for articular cartilage repair
S Trippel1*, M Cucchiarini2, H Madry2, S Shi1, and C Wang1
1Department of Orthopaedic Surgery, Indiana University School of Medicine
2Laboratory for Experimental Orthopaedics, Department of Orthopaedic Surgery, Saarland University Medical Center,
Homburg/Saar, Germany
The manuscript was received on 31 August 2006 and was accepted after revision for publication on 30 January 2007.
DOI: 10.1243/09544119JEIM237
Abstract: Articular cartilage serves as the gliding surface of joints. It is susceptible to damage
from trauma and from degenerative diseases. Restoration of damaged articular cartilage may
be achievable through the use of cell-regulatory molecules that augment the reparative activities
of the cells, inhibit the cells’ degradative activities, or both. A variety of such molecules have
been identiﬁed. These include insulin-like growth factor I, ﬁbroblast growth factor 2, bone
morphogenetic proteins 2, 4, and 7, and interleukin-1 receptor antagonist. It is now possible
to transfer the genes encoding such molecules into articular cartilage and synovial lining cells.
Although preliminary, data from in-vitro and in-vivo studies suggest that gene therapy can
deliver such potentially therapeutic agents to protect existing cartilage and to build new
cartilage.
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1 INTRODUCTION Articular cartilage is unusual in lacking an eﬀective
intrinsic capacity to repair itself when damaged. It
lacks a blood supply and, as a result, does not haveDamaged articular cartilage is an unsolved problem
in modern orthopaedics. Articular cartilage is the access to the reparative cells that are brought into
sites of injury in nearly all other tissues in the body.tissue which lines the weight-bearing surface of joints.
Its extraordinarily low coeﬃcient of friction enables Thus, defects caused by acute trauma tend to persist,
and the loss of cartilage associated with arthritisthe smooth supple pain-free motion of joints. Indeed,
early in life, it is generally possible to take smooth tends to be inexorably progressive [2].
Current medical treatments for arthritis are highlypain-free joint motion for granted. Unfortunately,
articular cartilage damage, manifested clinically as eﬀective in reducing the pain that it causes. However,
such treatments are ineﬀective in reversing thearthritis, becomes increasingly prevalent with increas-
ing age. Arthritis aﬄicts over one third of Americans course of the disease. As a result, the ultimate fate
of many arthritic joints is total joint replacementwho are 60–65 years old, and nearly half of those
70–75 years of age [1]. Because the elderly are one of surgery by implantation of metal, plastic, or ceramic
bearing surfaces as substitutes for the articular carti-the most rapidly growing segments of the population
in the USA and elsewhere, the problem of articular lage surface. Although such surgery arrests the
course of the disease, it does so not by restoring thecartilage damage is increasing in scope. Injury to this
tissue may also occur in youth. Trauma to joints can cartilage to normal, but by removing it altogether.
Such surgery also sets in motion a new form of pro-acutely damage articular cartilage. A typical example
is the focal loss of articular cartilage that occurs in gressive disease, that of joint replacement failure.
Many replaced joints fail through mechanisms suchathletic injuries to the knee. Although less common
than arthritis, this form of articular cartilage damage as wear, loosening, infection, and breakage. This
leads to further surgery to revise the replaced jointcan be similarly disabling.
that has failed, but the results of revision joint
* Corresponding author: Orthopaedic Surgery, Indiana University replacement are generally not as good as those of
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include surgical recruitment of subchondral cells The speciﬁc goal of the gene therapy determines
the speciﬁc protein, and hence the speciﬁc gene,[3, 4], cell implantation [5, 6], and tissue implant-
ation [3, 5, 6]. All these treatments have had some selected for use. A growth factor gene may be used
if the goal of gene therapy is to alter the behaviourclinical success, but none reliably restores the carti-
lage to normal and eﬀorts are ongoing to improve of surrounding cells. A gene encoding an enzyme
inhibitor may be selected if the goal is to inhibit carti-upon current articular cartilage repair methods.
A major hurdle to the development of eﬀective lage matrix degradation. Gene therapy may be
viewed as a drug delivery system that is able totherapies for articular cartilage repair is the lack of a
basic understanding of how cartilage is regulated in deliver an essentially pure agent to a highly speciﬁc
location in a delayed-release fashion. The technologythe normal joint and how this regulation is disrupted
in the arthritic joint. Despite this limited understand- for achieving gene transfer and protein production
is, however, not simple and is still under develop-ing, it is possible to view the ‘cause’ of arthritis as
an imbalance in articular cartilage homeostasis: ment.
loss of articular cartilage occurs when the level of
anabolic activity in the tissue falls below the level of
the catabolic activity [7]. From this perspective, one 3 SELECTION OF GENES FOR GENE THERAPY
approach to reversing the progress of articular carti-
lage damage would be to augment articular cartilage An important advantage of gene transfer as a poten-
tial approach to therapy for cartilage repair is theanabolic activities and/or to reduce its catabolic
activities [8]. wide variety of molecules that have been found to
augment the anabolic activity of articular chondro-Considerable progress has been made in the last
few years in identifying biological factors that aug- cytes. Most of these molecules are proteins that
function as cell-signalling agents that regulate cellment the reparative activity of articular chondro-
cytes, and also in identifying those responsible for behaviour. Harnessing this action has been achieved
for several growth factors in in-vitro and in-vivocartilage degradation. Less progress has been made
in developing methods of delivering these sub- models. Insulin-like growth factor I (IGF-I) stimulates
synthesis by chondrocytes of the two major buildingstances to damaged joints in a fashion that eﬀectively
restores the cartilage. For example, even when a pro- blocks of articular cartilage: aggrecan [11] and type
II collagen [12]. It also has a mild stimulatory eﬀecttein that is known to stimulate cartilage repair or in-
hibit cartilage degradation is delivered to a joint, it on chondrocyte proliferation and inhibits chondro-
cyte degradation of its surrounding matrix [13].may be ineﬀective because of rapid clearance from
the joint, or diﬃculty getting through the articular Fibroblast growth factor 2 (FGF-2) is mitogenic for
chondrocytes but appears to be capable of stimulat-cartilage matrix to act on the chondrocytes that it is
intended to stimulate [9, 10]. These problems may ing both reparative and degradative behaviour in
articular cartilage [8]. Members of the transformingpotentially be resolved by gene transfer technology.
growth factor (TGF-b) superfamily, including the
bone morphogenetic proteins (BMPs), are potent
regulators of chondrocytes. For example, in vitro,2 PRINCIPLES OF GENE THERAPY
BMP-2 maintained the articular chondrocyte pheno-
type in a long-term culture [14] and, in vivo, BMP-2Gene therapy is based on the principle that proteins,
including therapeutic proteins, are encoded by seg- signiﬁcantly improved the repair of articular cartilage
defects in rabbit knees analysed 1 year after treat-ments of deoxyribonucleic acid (DNA), or genes. A
speciﬁc DNA sequence serves as a template for the ment [15].
synthesis of a corresponding speciﬁc messenger
ribonucleic acid (mRNA). The construction of the
mRNA, termed transcription, occurs within the cell’s 4 CULTURE MODELS OF GENE TRANSFER
nucleus. The mRNA, in turn, serves as the template
for the synthesis of a speciﬁc protein. The construc- In-vitro models of chondrocyte gene transfer include
two-dimensional and three-dimensional cell cul-tion of the protein, termed translation, occurs in the
cell cytoplasm. The protein may then be secreted tures. The eﬀect of overexpression of several genes
has been studied in two-dimensional models, includ-into the extra-cellular environment. Gene therapy is
simply the insertion of a gene into a cell so that the ing IGF-I [16–18], BMP-2 [18], and TGF-b-1 [18, 19].
Three-dimensional systems more closely resemblecell now manufactures (through transcription and
then translation) the desired protein. the in-vivo environment of native chondrocytes
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embedded within their matrix. These conditions 5 ANIMAL MODELS OF GENE TRANSFER
enable chondrocytes to assume a spherical shape
Among the ﬁrst genes to be investigated in vivoand to avoid the phenotypic drift that may occur
was interleukin-1 receptor antagonist (IL-1Ra). Inter-when chondrocytes are grown and passaged over
leukin-1 is a cytokine produced by synovial cells andextended periods of time in monolayer [20, 21].
chondrocytes that appears to incite cartilage damageThree-dimensional systems that have been used for
in arthritis [34]. IL-1Ra is a protein that inhibitsgene transfer include pellet cultures [22], the trans-
the catabolic actions of interleukin-1. IL-1Ra geneplantation of genetically modiﬁed chondrocytes on
therapy has been investigated in mouse [35], rat [36],to cartilage explants [23–26], the creation of geneti-
rabbit [37–39], canine [40], and equine [41] modelscally modiﬁed tissue-engineered cartilage by attach-
of cartilage damage. The treatment reduced articularing modiﬁed chondrocytes to biomaterials such as
cartilage damage [38–40] and also reduced clinicalpolyglycolic acid [27], or the encapsulation of geneti-
signs of disease in the equine model [41]. IL-1Ra wascally modiﬁed chondrocytes in hydrogels such as
also used in the ﬁrst human arthritis gene therapyalginate [28–31].
trial [42]. In this study, the IL-1Ra gene was deliveredThe transplantation of genetically modiﬁed chond-
in autologous synovial cells to the hand joints ofrocytes on to articular cartilage explants in vitro
patients with rheumatoid arthritis. At the time ofcreates a chimeric tissue composed of modiﬁed cells
joint surgery 1 week later, the IL-1Ra gene was showntransplanted on to articular cartilage [23–26, 32].
to be expressed and IL-Ra protein was found in theThis model permits the study of the eﬀect of a poten-
joint.tial therapeutic gene on the formation of new carti-
Other promising candidates for gene therapy arelaginous tissue as well as on the underlying host
growth factors that stimulate anabolic activities bycartilage. Transplantation of articular chondrocytes
articular chondrocytes. These include IGF-I, FGF-2,that overexpressed human IGF-I was shown in such
TGF-b, BMP-2, and BMP-7. IGF-I gene transfer intoa model to both stimulate chondrocyte proliferation
articular chondrocytes stimulated chondrocyte pro-and matrix synthesis in the new tissue, and to
liferation and matrix synthesis and augmented the
increase DNA and glycosaminoglycan synthesis by
formation of neocartilage in in-vitro [16, 26] and
the underlying explant cartilage chondrocytes. These
in-vivo [31, 43, 44] models of articular cartilage
results suggest a paracrine eﬀect of the secreted gene
repair. Similar results have been obtained with FGF-2
product on distant chondrocytes embedded within
in vitro [25] and in vivo [45–47]. Direct intra-articular
their native matrix [26]. Transplantation of chondro-
transfer of the TGF-b gene raised intra-articular
cytes transduced with an adenoviral BMP-7 vector TGF-b protein levels [48] and intra-articular injection
also led to thicker new tissue in this model, suggest- of ﬁbroblasts transduced with the TGF-b gene stimu-
ing an enhanced matrix synthesis [24]. In contrast, lated cartilage repair in a cartilage defect model [49].
when chondrocytes overexpressing human FGF-2 Conversely, intra-articular gene transfer of a TGF-b
were transplanted, the cells in the new tissue showed inhibitor increased articular cartilage proteoglycan
a selective stimulation of mitogenic without eﬀects loss [50]. Gene transfer using BMP-2 [43], BMP-4
on matrix synthesis [25]. [51], and BMP-7 [52, 53] augmented intra-articular
Cartilage tissue engineering may also be improved cartilage formation in in-vivo models.
by the application of gene transfer technology.
Transfection of articular chondrocytes with human
IGF-I complementary deoxyribonucleic acid (cDNA)
6 TYPES OF GENE THERAPYaugmented the structural and functional properties
of tissue engineered cartilaginous constructs based
6.1 In-vitro gene therapyon a polyglycolic acid scaﬀold and generated in a
bioreactor [27]. The biosynthetic activity of chondro- In-vitro gene therapy entails the insertion of the
cytes encapsulated in alginate spheres was enhanced desired gene (transgene) into the recipient cells in a
by IGF-I [31] and FGF-2 [29] gene transfer. Similarly, cell or tissue culture environment. The cells are then
the transfer of SOX9, a transcription factor that placed into the relevant site in the body. This has the
acts only intracellularly, stimulated type-II collagen advantage of enabling gene transfer into a speciﬁc
expression in alginate spheres [33], and in pellet cul- population of cells, and the ability to test the cells
tures [22]. This ﬁnding suggests that tissue engineer- for successful gene expression. In-vitro methods
ing coupled with gene therapy based on intracrine have been used to deliver reporter genes [54], IGF-I
[16, 26], FGF-2 [25], BMP-2 [43], BMP-4 [51], BMP-7mechanisms may be feasible.
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[52, 53], TGF-b [49], and IL-1Ra [35, 37]. This is the ing a charge diﬀerential across the cell membrane.
Although this method has been applied to chondro-approach that was approved and then used in the
published human gene therapy study of IL-1Ra for cytes [58], its use has not been widespread. A variety
of cationic liposomes and other lipid-based systemsrheumatoid arthritis of the hand [42]. When using
adenoviral vectors, the in-vitro method has been have developed for gene transfer and are commer-
cially available. In a study that systematically com-shown to reduce the immune response that this
vector may elicit when used by in-vivo methods [43]. pared the ability of several cationic lipid preparations
to transfect bovine articular chondrocytes, consider-In-vitro gene therapeutic approaches also have the
advantage of delivering cells that may contribute to able diﬀerences were found among these reagents
[59]. Transfection with these lipid-based reagentsthe repair process. This may be of particular value
for the treatment of focal articular cartilage defects may be substantially increased by the use of co-
transfection agents [59]. Thus, a limitation of theseusing anabolic factors such as IGF-I, FGF-2, and
TGF-b, in which cells are needed to ﬁll the site of reagents is their sensitivity to cell type and trans-
fection conditions. Such non-viral gene transferdamage.
methods have the advantage of avoiding the risk of
insertional mutagenesis of retroviruses, the risk of6.2 In-vivo gene therapy
immunogenicity of adenoviruses, or the size limi-
In-vivo gene therapy involves the delivery of the
tation on transferred DNA that is associated with
desired gene directly into the body. This method has
AAVs. Non-viral methods also avoid the risk of
the advantage of avoiding the extra steps involved
acquiring viral competence. Because non-viral gene
in cell harvest, isolation, culture, and subsequent
transfer does not place the therapeutic gene into the
delivery. In theory, it should reduce the risk of com-
cell genome, the transferred gene (transgene) is not
plications such as cell contamination or phenotypic
transmitted to daughter cells if the cell divides. The
shifts, and the magnitude of processing costs. In-vivo
episomal (not integrated into the host cell genome)
approaches may be particularly suitable for gene
location of the transgene also destines the transgene
delivery to the synovium because these cells are
to be expressed for only a transient time period. This
readily accessible to injected agents. Articular chond-
transient expression is of great safety value for ana-
rocytes, in contrast, are embedded within a matrix
bolic genes whose product could cause excessive
that restricts diﬀusion of injected agents and may be
growth if overexpressed for prolonged periods. How-
expected to limit the access of such agents to the
ever, this feature also limits the potential value of the
chondrocytes. This approach has been applied in
method for chronic disorders that require long-
cartilage damage models to the delivery of IL-1Ra
lasting output of the gene product.
[36, 38, 39, 41], BMP-2 [43], IGF-I [44], FGF-2 [46],
TGF-b inhibitor [50], interleukin-4 [55], and the
7.2 Viral gene delivery
soluble tumour necrosis factor receptor 1 [56].
Localized in-vivo gene therapy could, in theory, Viruses in nature evolved to transfer genetic material.
The life cycle of wild-type viruses involves the trans-reduce the disadvantages of systemic viral dissemi-
nation. When adeno-associated virus (AAV) vectors fer of viral DNA or RNA into host cells. Virus-based
gene therapy builds on this innate ability by addingwere applied to articular cartilage defects by open
arthrotomy in the rat [57] or rabbit [46] knee, potentially therapeutic genes to the viral sequence
and, in some instances, by also removing portionstransgene product was subsequently found in the
defect repair tissue but, in both models, transgene of the viral genome that enable the viruses to be
harmful.product was also noted in the synovium. These results
indicate that, even with localized in-vivo delivery
into a joint, at least some systemic distribution 7.3 Retrovirus vectors
may occur.
Retroviruses include such evolutionarily successful
viruses as human immunodeﬁciency virus and
human T-lymphotropic viruses. An important advan-
7 GENE DELIVERY AGENTS
tage of these viruses for gene therapy is their ability
to incorporate into the genome of the host cell. This
7.1 Non-viral gene delivery
enables the transferred gene to be replicated during
cell division and to achieve long-term expression overA popular approach to transferring DNA into cells
employs physicochemical methods. Electroporation multiple cell generations. However, this feature also
imposes the safety issue of insertional mutagenesis.enables DNA to cross the cells membrane by generat-
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This may occur when the transferred gene is inserted relatively small (up to about 4.7 kilobases) genes.
This limitation may be resolved by exploiting theinto a region of the host cell’s DNA in such a way that
the insertion disrupts the function of a normal gene. attractive feature of rAAV genomes that they can be
linked together to increase the size of the genes toFor example, by disrupting the function of a tumour
suppressor gene, the gene transfer may inadvertently be transferred [68, 69].
promote cancer. This phenomenon has been blamed
for the development of leukaemia in some children 7.6 Lentivirus vectors
who received retroviral gene therapy in the late 1990s
Lentiviruses are a relative of retroviruses. Lentivirus[60]. Additional limitations of retroviruses as vectors
vectors are distinguished from oncogenic retrovirusare their inability to infect non-dividing cells and the
vectors by their ability to transduce non-dividingneed for special culture procedures to identify and
cells. Lentivirus vector-based gene delivery canselect cells that contain the transgene. Retroviruses
generate long-term transgene expression by incorpo-have, however, been demonstrated to be feasible
rating transgenes into the host cell genome. Twovectors for delivering exogenous genes to sites of
additional advantages of these vectors are theirarticular cartilage damage [51, 61].
ability to deliver large cDNAs into target cells and to
do so without inducing a host immune response7.4 Adenovirus vectors
against the transduced cells [70]. Lentivirus vectors
Adenovirus vectors are among the most successful have been successfully used to deliver genes to syno-
vectors available for gene transfer. They often gener- vium in vivo [71] and to chondrocytes in vitro [72].
ate high transfection eﬃciency and high levels of The safety of these vectors and the regulation of
transgene product in a variety of cell types. Adeno- expression of their transgenes are currently under
viral vectors have been used in in-vitro and in-vivo investigation.
models of cartilage damage, including models of
inﬂamatory arthritis [44], osteoarthritis [41, 48], and
chondral defects [32, 53, 62]. They are the only viral
8 FUTURE DIRECTIONS
vector used to date in human joint disease [42].
Unfortunately, adenoviral vectors are often immuno-
The potential applications of gene therapy for carti-
genic and may stimulate a host response. This reac-
lage repair are many. Gene transfer technology can,
tion may be severe and led to the highly publicized
in theory, be applied to inﬂammatory joint disease
death of a gene therapy patient in a phase I clinical
such as rheumatoid arthritis, degenerative joint
trial [63]. Even inmilder form, this phenomenonmay
disease such as osteoarthritis or post-traumatic
be problematic. In the ﬁeld of cartilage gene therapy,
arthritis, and to acute cartilage loss, such as damage
it is thought to be responsible for the paradoxical
due to athletic injuries. Considerable progress has
inhibition of proteoglycan synthesis in chondrocytes
been made in bringing these applications towards
that received the IL-1Ra gene, a treatment that would
fruition in articular cartilage disease. The technology
be expected to have the opposite eﬀect [64].
has been shown to be eﬀective at a proof-of-concept
level for all these applications in both in-vitro and
7.5 Adeno-associated virus vectors
in-vivomodels. However, many unanswered questions
remain (Table 1). What is the optimal vector? IsAAVs are replication-defective parvoviruses that have
the advantage, for gene therapy, of being non- in-vivo gene therapy superior to in-vitro gene therapy,
or vice versa? What is the short-term and, perhapspathogenic in humans. They lack the immuno-
genicity of adenoviruses and the risk of insertional more importantly, the long-term safety of the genes
and gene products that would be used to treat jointmutagenesis of retroviruses. Early experience with
recombinant AAVs suggests that these viruses may disease? Is gene transfer technology robust enough
to be useful on its own, or should eﬀorts be intensi-serve as eﬀective vectors for chondrocyte and syn-
ovial cell transfection in vitro [45, 57, 65] and in vivo ﬁed to combine it with tissue engineering tech-
nology? Probably, the answer to all of these questions[36, 46, 47, 55, 56, 66, 67]. To date, however, available
data on these vectors remains limited in comparison is ‘it depends’. Just as the disorders that aﬄict carti-
lage are diverse and of multifactorial aetiology,with adenoviral vectors. Both an advantage and a
limitation of AAVs as a gene therapy vector is its size. so eﬀective treatments for them will be diverse and
will probably require multiple elements. As ongoingAs a particularly small virus, it may have access to
sites that are not accessible to larger viral vectors. research provides answers to these questions, and
as understanding of the mechanisms underlyingHowever, its size also means that it can hold only
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Table 1 Progress in articular cartilage gene therapy
Accomplished To be accomplished
Gene transfer to articular chondrocytes Optimal gene transfer method
Transgene protein production by chondrocytes Best protein(s) to transfer
Enhanced chondrogenesis in vitro Long-term safety
Enhanced chondrogenesis in vivo (animal models) Durable eﬃcacy
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